Addressing financial barriers to patient participation in clinical trials: ASCO policy statement

Karen M. Winkfield, Jonathan K. Phillips, Steven Joffe, Michael Halpern, Dana S. Wollins, Beverly Moy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Research conducted through clinical trials is essential for evaluating new treatment modalities, establishing new standards of cancer care, and ultimately improving and prolonging the lives of patients with cancer. However, participation in trials has been low, and this is attributable to various factors including patient financial barriers. Such financial barriers include the rising cost of cancer care; a lack of transparency in coverage policy; and the perception of ethical, compliance, or institutional impediments to patient financial support. ASCO convened a roundtable discussion with a variety of stakeholders to define the scope of the problem, as well as to identify clinical practice and policy solutions applicable at the institutional and system-wide levels. This statement summarizes key discussions from the ASCO Roundtable, as well as findings from the literature, and provides ASCO's recommendations for overcoming financial barriers that may otherwise prevent participation in clinical trials. These recommendations broadly address the following key areas: (1) improving the policy environment for coverage of clinical trials; (2) facilitating transparency among providers, patients, and payers for trial-related out-of-pocket costs; (3) refuting the specter of inducement to enable targeted financial support for patients; and (4) improving the available data on costs of cancer clinical trials.

Original languageEnglish (US)
Pages (from-to)3331-3339
Number of pages9
JournalJournal of Clinical Oncology
Volume36
Issue number33
DOIs
StatePublished - Nov 20 2018
Externally publishedYes

Fingerprint

Patient Participation
Clinical Trials
Financial Support
Neoplasms
Costs and Cost Analysis
Standard of Care
Health Expenditures
Compliance
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Addressing financial barriers to patient participation in clinical trials : ASCO policy statement. / Winkfield, Karen M.; Phillips, Jonathan K.; Joffe, Steven; Halpern, Michael; Wollins, Dana S.; Moy, Beverly.

In: Journal of Clinical Oncology, Vol. 36, No. 33, 20.11.2018, p. 3331-3339.

Research output: Contribution to journalArticle

Winkfield, Karen M. ; Phillips, Jonathan K. ; Joffe, Steven ; Halpern, Michael ; Wollins, Dana S. ; Moy, Beverly. / Addressing financial barriers to patient participation in clinical trials : ASCO policy statement. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 33. pp. 3331-3339.
@article{053487ec02ca4555ad205d62467b300b,
title = "Addressing financial barriers to patient participation in clinical trials: ASCO policy statement",
abstract = "Research conducted through clinical trials is essential for evaluating new treatment modalities, establishing new standards of cancer care, and ultimately improving and prolonging the lives of patients with cancer. However, participation in trials has been low, and this is attributable to various factors including patient financial barriers. Such financial barriers include the rising cost of cancer care; a lack of transparency in coverage policy; and the perception of ethical, compliance, or institutional impediments to patient financial support. ASCO convened a roundtable discussion with a variety of stakeholders to define the scope of the problem, as well as to identify clinical practice and policy solutions applicable at the institutional and system-wide levels. This statement summarizes key discussions from the ASCO Roundtable, as well as findings from the literature, and provides ASCO's recommendations for overcoming financial barriers that may otherwise prevent participation in clinical trials. These recommendations broadly address the following key areas: (1) improving the policy environment for coverage of clinical trials; (2) facilitating transparency among providers, patients, and payers for trial-related out-of-pocket costs; (3) refuting the specter of inducement to enable targeted financial support for patients; and (4) improving the available data on costs of cancer clinical trials.",
author = "Winkfield, {Karen M.} and Phillips, {Jonathan K.} and Steven Joffe and Michael Halpern and Wollins, {Dana S.} and Beverly Moy",
year = "2018",
month = "11",
day = "20",
doi = "10.1200/JCO.18.01132",
language = "English (US)",
volume = "36",
pages = "3331--3339",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Addressing financial barriers to patient participation in clinical trials

T2 - ASCO policy statement

AU - Winkfield, Karen M.

AU - Phillips, Jonathan K.

AU - Joffe, Steven

AU - Halpern, Michael

AU - Wollins, Dana S.

AU - Moy, Beverly

PY - 2018/11/20

Y1 - 2018/11/20

N2 - Research conducted through clinical trials is essential for evaluating new treatment modalities, establishing new standards of cancer care, and ultimately improving and prolonging the lives of patients with cancer. However, participation in trials has been low, and this is attributable to various factors including patient financial barriers. Such financial barriers include the rising cost of cancer care; a lack of transparency in coverage policy; and the perception of ethical, compliance, or institutional impediments to patient financial support. ASCO convened a roundtable discussion with a variety of stakeholders to define the scope of the problem, as well as to identify clinical practice and policy solutions applicable at the institutional and system-wide levels. This statement summarizes key discussions from the ASCO Roundtable, as well as findings from the literature, and provides ASCO's recommendations for overcoming financial barriers that may otherwise prevent participation in clinical trials. These recommendations broadly address the following key areas: (1) improving the policy environment for coverage of clinical trials; (2) facilitating transparency among providers, patients, and payers for trial-related out-of-pocket costs; (3) refuting the specter of inducement to enable targeted financial support for patients; and (4) improving the available data on costs of cancer clinical trials.

AB - Research conducted through clinical trials is essential for evaluating new treatment modalities, establishing new standards of cancer care, and ultimately improving and prolonging the lives of patients with cancer. However, participation in trials has been low, and this is attributable to various factors including patient financial barriers. Such financial barriers include the rising cost of cancer care; a lack of transparency in coverage policy; and the perception of ethical, compliance, or institutional impediments to patient financial support. ASCO convened a roundtable discussion with a variety of stakeholders to define the scope of the problem, as well as to identify clinical practice and policy solutions applicable at the institutional and system-wide levels. This statement summarizes key discussions from the ASCO Roundtable, as well as findings from the literature, and provides ASCO's recommendations for overcoming financial barriers that may otherwise prevent participation in clinical trials. These recommendations broadly address the following key areas: (1) improving the policy environment for coverage of clinical trials; (2) facilitating transparency among providers, patients, and payers for trial-related out-of-pocket costs; (3) refuting the specter of inducement to enable targeted financial support for patients; and (4) improving the available data on costs of cancer clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85056770662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056770662&partnerID=8YFLogxK

U2 - 10.1200/JCO.18.01132

DO - 10.1200/JCO.18.01132

M3 - Article

AN - SCOPUS:85056770662

VL - 36

SP - 3331

EP - 3339

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -